Business
Tempus Named to TIME's 10 Most Influential Health and Life Science Companies of 2026
CHICAGO, April 28, 2026--Tempus AI, Inc. (NASDAQ: TEM), a technology company advancing precision medicine through the practical application of artificial intelligence, today announced it has been named to TIME’s 10 Most Influential Health and Life Science Companies of 2026. The inaugural TIME100 Companies: Industry Leaders list, an expansion of the TIME100 Most Influential Companies issue, recognizes organizations shaping the future of their sectors through extraordinary impact and innovation.
About this update from Tempus Ai, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/bca4e18fb45f3114dfe1ece392038503"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3IOJGOafJuzFcm7BnQISKw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MA--/https://media.zenfs.com/en/business-wire.com/bca4e18fb45f3114dfe1ece392038503","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/e9AFcfpQV4sY1bqGL_8XNA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0/https://media.zenfs.com/en/business-wire.com/bca4e18fb45f3114dfe1ece392038503","width":1024,"height":512}},"lazy":false},{"type":"text","content":"CHICAGO, April 28, 2026--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company advancing precision medicine through the practical application of artificial intelligence, today announced it has been named to TIME’s 10 Most Influential Health and Life Science Companies of 2026. The inaugural TIME100 Companies: Industry Leaders list, an expansion of the TIME100 Most Influential Companies issue, recognizes organizations shaping the future of their sectors through extraordinary impact and innovation.","length":515,"tagName":"p"},{"type":"text","content":"Tempus was recognized for its leadership in bridging the gap between data and technology to make genomic testing and clinical analysis more intelligent for patients. In naming Tempus to its list of the most influential companies, TIME highlighted the impact of xT CDx, Tempus’ FDA-approved 648-gene tissue-based NGS test for molecular profiling of all malignant solid tumors. The recognition also noted Tempus’ acquisition of Ambry Genetics, which integrated comprehensive germline and pediatric capabilities into the Tempus ecosystem. Additionally, TIME underscored Tempus’ collaborations with industry leaders, including its collaboration with AstraZeneca and Pathos AI to develop the largest multimodal foundation model in oncology.","length":735,"tagName":"p"},{"type":"text","content":""This recognition from TIME speaks to our team’s focus on building a more connected and data-driven healthcare ecosystem," said Eric Lefkofsky, Founder and CEO of Tempus AI. "We started Tempus with the belief that every patient should benefit from the data of those who...